Nephrotic Syndrome Reported With Everolimus, Voriconazole

This article originally appeared here.
Share this content:
Nephrotic Syndrome Reported With Everolimus, Voriconazole
Nephrotic Syndrome Reported With Everolimus, Voriconazole

FRIDAY, July 7, 2017 (HealthDay News) -- In a case report published online June 29 in the Journal of Clinical Pharmacy and Therapeutics, nephrotic syndrome is diagnosed in a 32-year-old female with relapsed Hodgkin's lymphoma who was on everolimus and initiated voriconazole.

Phu N. Tran, M.D., and Lauren Pinter-Brown, M.D., from the University of California Irvine School of Medicine, present the case of a 32-year-old female with relapsed Hodgkin's lymphoma who was treated with everolimus for five years.

The authors note that about two months after initiation of voriconazole, the patient developed nephrotic syndrome. She was taking 10 mg everolimus once daily and 200 mg voriconazole twice daily. Thrombotic microangiopathic vasculopathy was revealed in renal biopsy, as well as thin basement membrane nephropathy. Her nephrotic syndrome rapidly improved with discontinuation of everolimus and voriconazole.

"We provide in-depth analysis of the underlying mechanisms of everolimus-induced nephrotic syndrome and hypothesize that voriconazole likely decreased everolimus metabolism," the authors write. "In the era of targeted therapy for cancer, health care providers should be aware of the drug-drug interaction between everolimus (as well as tyrosine kinase inhibitors) and cytochrome P450 CYP3A4 inhibitors (i.e., voriconazole)."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »